Online Trial Tracker - Larvol Sigma

Chromosome Disorders

dasatinib

Phase 3

Welcome, Profile Billing Logout

2 Trials

All TrialsPhase 3

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

dasatinib / Generic mfg.

DASISION, NCT00481247 / 2006-005712-27: A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

	EHA 2016
	May 2016 - May 2016: EHA 2016
	ASCO 2016
	May 2016 - May 2016: ASCO 2016
	vs. Imatinib in treatment naive CML pts
	Dec 2013 - Dec 2013: vs. Imatinib in treatment naive CML pts
	vs. Imatinib in treatment naive CML pts
	Dec 2013 - Dec 2013: vs. Imatinib in treatment naive CML pts
	P3 data - ASCO
	Jun 2012 - Jun 2012: P3 data - ASCO
	P3 data
	Dec 2011 - Dec 2011: P3 data
	Data
	Nov 2011 - Nov 2011: Data
	P3 data
	Nov 2011 - Nov 2011: P3 data
	Data
	Oct 2011 - Oct 2011: Data
	Data
	May 2011 - May 2011: Data
	P3 data
	May 2011 - May 2011: P3 data
	P3 data
	Apr 2011 - Apr 2011: P3 data
	Data
	Apr 2011 - Apr 2011: Data
	P3 data
	Dec 2010 - Dec 2010: P3 data
	P3 data
	Dec 2010 - Dec 2010: P3 data
	Data
	Dec 2010 - Dec 2010: Data
	Data
	Dec 2010 - Dec 2010: Data
More

Completed

547

Japan, US, Europe, RoW

Dasatinib, Sprycel®, BMS-354825, Imatinib

Bristol-Myers Squibb

Myeloid Leukemia, Chronic

12/09

12/15

NCT00349518 / 2006-001279-39: Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Withdrawn

2/3

Europe, RoW

Dasatinib

Bristol-Myers Squibb

Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia

01/07

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites